Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. develops and commercializes medicines for hereditary angioedema and other rare diseases. Its commercial product ORLADEYO® (berotralstat) is an oral, once-daily plasma kallikrein inhibitor for HAE, and company updates commonly report ORLADEYO revenue, commercial execution, and financial results.
BioCryst news also covers pipeline and portfolio developments, including investigational plasma kallikrein inhibitor navenibart, rare-disease research programs, licensing arrangements, acquisitions, senior R&D leadership changes, investor conference activity, and Nasdaq inducement equity grants tied to new employee hiring.
BioCryst Pharmaceuticals (BCRX) has priced an underwritten public offering of 18,711,113 shares at $4.50 per share, alongside pre-funded warrants for an additional 3,511,111 shares at $4.49 each. The total gross proceeds are expected to reach $100 million before expenses. The offering will close around June 1, 2020, pending customary conditions. Proceeds will support various corporate initiatives, including development of berotralstat and BCX9930, among others. J.P. Morgan and Piper Sandler are managing the offering.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced it will present new data on berotralstat (BCX7353), an oral therapy for hereditary angioedema (HAE), at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) digital congress from June 6-8. Key data include findings from the APeX-S and APeX-2 studies, showcasing berotralstat's long-term safety and significant reduction in HAE attacks. As regulatory approvals approach in the U.S., Japan, and EU, Dr. William Sheridan emphasized berotralstat's potential impact on HAE patients.
Summary not available.
BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at the Bank of America 2020 Healthcare Conference on May 14, 2020 at 9:00 a.m. ET and at the 2020 RBC Capital Markets Global Healthcare Conference on May 20, 2020 at 3:40 p.m. ET. Both events will be conducted virtually.
Investors can access live webcasts and replays of these presentations on BioCryst's website. The company focuses on developing novel, oral treatments for rare diseases, including berotralstat for hereditary angioedema and BCX9930, an oral Factor D inhibitor.
BioCryst Pharmaceuticals (BCRX) announced the grant of inducement stock options totaling 525,000 shares to two newly-hired employees, including 500,000 shares to CFO Anthony Doyle. The options, granted on April 30, 2020, have an exercise price of $3.91, equal to the stock's closing price on the previous day. Mr. Doyle's options include a vesting schedule tied to his employment status, while the other employee's options vest over four years. These grants comply with NASDAQ Listing Rule 5635(c)(4), aimed at attracting talent to support BioCryst's ongoing development in rare diseases.